Clinical and pharmacological profile of benznidazole for treatment of Chagas disease

References

• World Health Organization. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. In: Weekly epidemiological record. Geneva: World Health Organization; 2015. p. 33–40.
   Google Scholar
• Manne-Goehler J, Umeh CA, Montgomery SP, et al. Estimating the burden of Chagas disease in the United States. PLoS Negl Trop Dis. 2016;10(11):e0005033.
   PubMed Web of Science ®Google Scholar
• Basile L, Jansa J, Salamanca D, et al. Chagas disease in European countries: the challenge of a surveillance system. Euresurveillance. 2011;16(37):9.
   Web of Science ®Google Scholar
• Lee BY, Bacon KM, Bottazzi ME, et al. Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis. 2013;13(4):342–348.
   PubMed Web of Science ®Google Scholar
• Franco-Paredes C, Von A, Hidron A, et al. Chagas disease: an impediment in achieving the millennium development goals in Latin America. BMC Int Health Hum Rights. 2007;7(1):7.
   PubMedGoogle Scholar
• Bocchi EA. Heart failure in South America. Curr Cardiol Rev. 2013;9(2):147–156.
   PubMedGoogle Scholar
• Sosa-Estani S, Segura EL. Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr Opin Infect Dis. 2006;19(6):583–587.
   PubMed Web of Science ®Google Scholar
• Cerisola JA. Chemotherapy of Chagas’ infection in man. In Chagas’ Disease Symposium Proceedings pp. 35–47. Pan American Health Organization; Washington, DC: 1977.
   Google Scholar
• Brener Z. Recent advances in the chemotherapy of Chagas’ disease. Memórias Do Instituto Oswaldo Cruz. 1984;79:149–155.
   Google Scholar
• Viotti R, Alarcón de Noya B, Araujo-Jorge T, et al. Towards a paradigm shift in the treatment of chronic Chagas disease. Antimicrob Agents Chemother. 2014;58(2):635–639.
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic chagas disease with benznidazole versus no treatment: A nonrandomized trial. Ann Intern Med. 2006;144(10):724–734.
   PubMed Web of Science ®Google Scholar
• Fabbro DL, Streiger ML, Arias ED, et al. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop. 2007;40(1):1–10.
   PubMed Web of Science ®Google Scholar
• Tratamiento Etiológico de la Enfermedad de Chagas: conclusiones de una Consulta Técnica. Washington, DC: Pan American Health Organization; Rio de Janeiro, Brasil: Fundación Oswaldo Cruz; 1999.
   Google Scholar
• Sosa-Estani S, Segura EL. Integrated control of Chagas disease for its elimination as public health problem–a review. Mem Inst Oswaldo Cruz. 2015;110(3):289–298.
   PubMed Web of Science ®Google Scholar
• Dias JCP, Ramos AN Jr., Gontijo ED, et al. Second Brazilian consensus on Chagas disease, 2015. Rev Soc Bras Med Trop. 2016;49:3–60.
   Web of Science ®Google Scholar
• Chaben I, editor. Pautas para la atención al paciente infectado con Trypanosoma cruzi (Enfermedad de Chagas). Argentina, Buenos Aires: Ministerio de Salud; 2015.
   Google Scholar
• Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of chagas disease in the united states: a systematic review. JAMA. 2007;298(18):2171–2181.
   PubMed Web of Science ®Google Scholar
• Stimpert KK, Montgomery SP. Physician awareness of Chagas disease, USA. Emerg Infect Dis. 2010;16(5):871–872.
   PubMed Web of Science ®Google Scholar
• Manne-Goehler J, Reich MR, Wirtz VJ. Access to care for Chagas disease in the United States: a health systems analysis. Am J Trop Med Hyg. 2015;93(1):108–113.
   PubMed Web of Science ®Google Scholar
• Forsyth CJ, Hernandez S, Flores CA, et al. “It’s like a phantom disease”: patient perspectives on access to treatment for Chagas disease in the United States. Am J Trop Med Hyg. 2018.
   PubMed Web of Science ®Google Scholar
• Raether W, Hanel H. Nitroheterocyclic drugs with broad spectrum activity. Parasitol Res. 2003;90(Supp 1):S19–S39.
   PubMedGoogle Scholar
• McCalla DR. Mutagenicity of nitrofuran derivatives: review. Environ Mutagen. 1983;5(5):745–765.
   PubMedGoogle Scholar
• Wilkinson SR, Bot C, Kelly JM, et al. Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives. Curr Top Med Chem. 2011;11(16):2072–2084.
   PubMed Web of Science ®Google Scholar
• Patterson S, Wyllie S. Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects. Trends Parasitol. 2014;30(6):289–298.
   PubMed Web of Science ®Google Scholar
• Keenan M, Chaplin JH. A new era for chagas disease drug discovery? Prog Med Chem. 2015;54:185–230.
   PubMedGoogle Scholar
• Grunberg E, Beskid G, Cleeland R, et al. Antiprotozoan and antibacterial activity of 2-nitroimidazole derivatives. Antimicrob Agents Chemother (Bethesda). 1967;7:513–519.
   PubMedGoogle Scholar
• Cucunuba ZM, Manne-Goehler JM, Diaz D, et al. How universal is coverage and access to diagnosis and treatment for Chagas disease in Colombia? A health systems analysis. Soc Sci Med. 2017;175:187–198.
   PubMed Web of Science ®Google Scholar
• Wilkinson SR, Kelly JM. Trypanocidal drugs: mechanisms, resistance and new targets. Expert Rev Mol Med. 2009;11:e31.
   PubMed Web of Science ®Google Scholar
• Docampo R, Moreno SN. Free radical metabolites in the mode of action of chemotherapeutic agents and phagocytic cells on Trypanosoma cruzi. Rev Infect Dis. 1984;6(2):223–238.
   PubMedGoogle Scholar
• Trochine A, Creek DJ, Faral-Tello P, et al. Benznidazole biotransformation and multiple targets in Trypanosoma cruzi revealed by metabolomics. PLoS Negl Trop Dis. 2014;8(5):e2844.
   PubMed Web of Science ®Google Scholar
• Murta SM, Ropert C, Alves RO, et al. In-vivo treatment with benznidazole enhances phagocytosis, parasite destruction and cytokine release by macrophages during infection with a drug-susceptible but not with a derived drug-resistant Trypansoma cruzi population. Parasite Immunol. 1999;21(10):535–544.
   PubMed Web of Science ®Google Scholar
• Lambertucci F, Motino O, Villar S, et al. Benznidazole, the trypanocidal drug used for Chagas disease, induces hepatic NRF2 activation and attenuates the inflammatory response in a murine model of sepsis. Toxicol Appl Pharmacol. 2017;315:12–22.
   PubMed Web of Science ®Google Scholar
• Perin L, Moreira Da Silva R, Fonseca KD, et al. Pharmacokinetics and tissue distribution of benznidazole after oral administration in mice. Antimicrob Agents Chemother. 2017;61(4).
   Web of Science ®Google Scholar
• de Toranzo EG, Masana M, Castro JA. Administration of benznidazole, a chemotherapeutic agent against Chagas disease, to pregnant rats. Covalent binding of reactive metabolites to fetal and maternal proteins. Arch Int Pharmacodyn Ther. 1984;272(1):17–23.
   PubMedGoogle Scholar
• Workman P, White RA, Walton MI. Preclinical pharmacokinetics of benznidazole. Br J Cancer. 1984;50(3):291–303.
   PubMed Web of Science ®Google Scholar
• Application 209570 (Benznidazole). Center for Drug Evaluation Research, U.S. Food and Drug Administration; Silver Spring, Maryland: 2017.
   Google Scholar
• Perdomo VG, Rigalli JP, Luquita MG, et al. Up-regulation of ATP-binding cassette transporters in the THP-1 human macrophage cell line by the antichagasic benznidazole. Mem Inst Oswaldo Cruz. 2016;111(11):707–711.
   PubMed Web of Science ®Google Scholar
• Polak A, Richle R. Mode of action of the 2-nitroimidazole derivative benznidazole. Ann Trop Med Parasitol. 1978;72(1):45–54.
   PubMed Web of Science ®Google Scholar
• Neal RA, van Bueren J. Comparative studies of drug susceptibility of five strains of Trypanosoma cruzi in vivo and in vitro. Trans R Soc Trop Med Hyg. 1988;82(5):709–714.
   PubMed Web of Science ®Google Scholar
• Revollo S, Oury B, Laurent JP, et al. Trypanosoma cruzi: impact of clonal evolution of the parasite on its biological and medical properties. Experimental Parasitology. 1998;89(1):30–39.
   PubMed Web of Science ®Google Scholar
• Canavaci AM, Bustamante JM, Padilla AM, et al. In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds. PLoS Negl Trop Dis. 2010;4(7):e740.
   PubMed Web of Science ®Google Scholar
• Moreno M, D’Avila DA, Silva MN, et al. Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease. Mem Inst Oswaldo Cruz. 2010;105(7):918–924.
   PubMed Web of Science ®Google Scholar
• Moraes CB, Giardini MA, Kim H, et al. Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development. Sci Rep. 2014;4:4703.
   PubMed Web of Science ®Google Scholar
• Chatelain E. Chagas disease drug discovery: towarda New Era. J Biomol Screen. 2015;20(1):22–35.
   PubMedGoogle Scholar
• Chatelain E, Konar N. Translational challenges of animal models in Chagas disease drug development: a review. Drug Des Devel Ther. 2015;9:4807–4823.
   PubMed Web of Science ®Google Scholar
• Teston AP, Monteiro WM, Reis D, et al. In vivo susceptibility to benznidazole of Trypanosoma cruzi strains from the western Brazilian Amazon. Trop Med Int Health. 2013;18(1):85–95.
   PubMed Web of Science ®Google Scholar
• Teixeira AR, Calixto MA, Teixeira ML. Chagas’ disease: carcinogenic activity of the antitrypanosomal nitroarenes in mice. Mutat Res. 1994;305(2):189–196.
   PubMedGoogle Scholar
• Romanha AJ, Alves RO, Murta SM, et al. Experimental chemotherapy against Trypanosoma cruzi infection: essential role of endogenous interferon-gamma in mediating parasitologic cure. J Infect Dis. 2002;186(6):823–828.
   PubMed Web of Science ®Google Scholar
• Bustamante JM, Craft JM, Crowe BD, et al. New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice. J Infect Dis. 2014;209(1):150–162.
   PubMed Web of Science ®Google Scholar
• Santos FM, Mazzeti AL, Caldas S, et al. Chagas cardiomyopathy: the potential effect of benznidazole treatment on diastolic dysfunction and cardiac damage in dogs chronically infected with Trypanosoma cruzi. Acta tropica. 2016;161:44–54.
   PubMed Web of Science ®Google Scholar
• Garcia S, Ramos CO, Senra JF, et al. Treatment with benznidazole during the chronic phase of experimental Chagas’ disease decreases cardiac alterations. Antimicrob Agents Chemother. 2005;49(4):1521–1528.
   PubMed Web of Science ®Google Scholar
• Guedes P, Veloso VM, Tafuri WL, et al. The dog as model for chemotherapy of the Chagas’ disease. Acta tropica. 2002;84(1):9–17.
   PubMed Web of Science ®Google Scholar
• Diniz L, Caldas IS, Guedes P, et al. Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrob Agents Chemother. 2010;54(7):2979–2986.
   PubMed Web of Science ®Google Scholar
• Santos FM, Lima WG, Gravel AS, et al. Cardiomyopathy prognosis after benznidazole treatment in chronic canine Chagas’ disease. J Antimicrob Chemother. 2012;67(8):1987–1995.
   PubMed Web of Science ®Google Scholar
• Lewis MD, Francisco AF, Taylor MC, et al. A new experimental model for assessing drug efficacy against Trypanosoma cruzi infection based on highly sensitive in vivo imaging. J Biomol Screen. 2015;20(1):36–43.
   PubMedGoogle Scholar
• Francisco AF, Jayawardhana S, Lewis MD, et al. Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage. Sci Rep. 2016;6:35351.
   PubMed Web of Science ®Google Scholar
• Ferreira RC, Ferreira LC. Mutagenicity of nifurtimox and benznidazole in the Salmonella/microsome assay. Braz J Med Biol Res = Revista Brasileira de Pesquisas Medicas Biologicas. 1986;19(1):19–25.
   PubMed Web of Science ®Google Scholar
• Gorla NB, Castro JA. Micronucleus formation in bone marrow of mice treated with nifurtimox or benznidazole. Toxicol Lett. 1985;25(3):259–263.
   PubMed Web of Science ®Google Scholar
• Villarreal D, Nirde P, Hide M, et al. Differential gene expression in benznidazole-resistant Trypanosoma cruzi parasites. Antimicrob Agents Chemother. 2005;49(7):2701–2709.
   PubMed Web of Science ®Google Scholar
• Campos MC, Castro-Pinto DB, Ribeiro GA, et al. P-glycoprotein efflux pump plays an important role in Trypanosoma cruzi drug resistance. Parasitol Res. 2013;112(6):2341–2351.
   PubMed Web of Science ®Google Scholar
• Campos MC, Leon LL, Taylor MC, et al. Benznidazole-resistance in Trypanosoma cruzi: evidence that distinct mechanisms can act in concert. Mol Biochem Parasitol. 2014;193(1):17–19.
   PubMed Web of Science ®Google Scholar
• Zingales B, Araujo RGA, Moreno M, et al. A novel ABCG-like transporter of Trypanosoma cruziis involved in natural resistance to benznidazole. Memórias Do Instituto Oswaldo Cruz. 2015;110:433–444.
   PubMed Web of Science ®Google Scholar
• Campos MC, Phelan J, Francisco AF, et al. Genome-wide mutagenesis and multi-drug resistance in American trypanosomes induced by the front-line drug benznidazole. Sci Rep. 2017;7(1):14407.
   PubMedGoogle Scholar
• Morillo CA, Marin-Neto JA, Avezum A, et al. Randomized trial of benznidazole for chronic Chagas’ cardiomyopathy. New England J Med. 2015;373(14):1295–1306.
   PubMed Web of Science ®Google Scholar
• Ferreira HD. Clinico-therapeutic trial with benzonidazole in Chagas’ disease. Rev Inst Med Trop Sao Paulo. 1976;18(5):357–364.
   PubMedGoogle Scholar
• Barclay CA, Cerisola JA. Aspectos farmacológicos e resultados terapéuticos do benzonidazol novo agente quimioterapico para tratamiento da infeccao de Chagas. Prensa Med Argent. 1978;65:239–244.
   Google Scholar
• Schenone H, Concha L, Aranda R, et al. Chemotherapeutic activity of a nitroimidazolacetamide compound in chronic chagasic infection. Bol Chil Parasitol. 1975;30(3–4):91–94.
   PubMedGoogle Scholar
• Raaflaub J, Ziegler WH. Single-dose pharmacokinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung. 1979;29(10):1611–1614.
   PubMed Web of Science ®Google Scholar
• Raaflaub J. Multiple-dose kinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung. 1980;30(12):2192–2194.
   PubMed Web of Science ®Google Scholar
• Roberts JT, Bleehen NM, Lee FY, et al. A phase I study of the combination of benznidazole and CCNU in man. Int J Radiat Oncol Biol Phys. 1984;10(9):1745–1748.
   PubMed Web of Science ®Google Scholar
• Roberts JT, Bleehen NM. Benznidazole with CCNU: a clinical phase I toxicity study. Int J Radiat Oncol Biol Phys. 1985;11(2):331–334.
   PubMed Web of Science ®Google Scholar
• Bisio M, Altcheh J, Lattner J, et al. Benznidazole treatment of chagasic encephalitis in pregnant woman with AIDS. Emerg Infect Dis. 2013;19(9):1490–1492.
   PubMed Web of Science ®Google Scholar
• Molina I, Salvador F, Sanchez-Montalva A, et al. Pharmacokinetics of benznidazole in healthy volunteers and implications in future clinical trials. Antimicrob Agents Chemother. 2017;61(4).
   Web of Science ®Google Scholar
• Sgambatti de Andrade ALS, Zicker F, de Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet. 1996;348(9039):1407–1413.
   PubMed Web of Science ®Google Scholar
• Sosa Estani S, Segura EL, Ruiz AM, et al. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas disease. Am J Trop Med Hyg. 1998;59(4):526–529.
   PubMed Web of Science ®Google Scholar
• Altcheh J, Moscatelli G, Moroni S, et al. Adverse events after the use of benznidazole in infants and children with Chagas disease. Pediatrics. 2011;127(1):e212–e218.
   PubMed Web of Science ®Google Scholar
• Altcheh J, Ribeiro I, Alves F, et al. Population pharmacokinetics of benznidazole in children and adults with Chagas disease. In: American society of tropical medicine and hygiene. Annual Meeting, American Society of Tropical Medicine and Hygiene. November 13–17, Washington (DC); 2013.
   Google Scholar
• Wiens MO, Kanters S, Mills E, et al. Systematic review and meta-analysis of the pharmacokinetics of benznidazole in the treatment of Chagas disease. Antimicrob Agents Chemother. 2016;60(12)7035–7042.
   PubMed Web of Science ®Google Scholar
• Torrico F, Gascon J, Ortiz L, et al. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. Lancet Infect Dis. 2018;18(4):419–430.
   PubMed Web of Science ®Google Scholar
• Barreira F. Update on current clinical trials for improving etiological treatment of Chagas disease. In: American society of tropical medicine and hygiene. Annual Meeting, American Society of Tropical Medicine and Hygiene. November 5–9, Baltimore (MD); 2017.
   Google Scholar
• Molina I, Gómez I Prat J, Salvador F, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. New England J Med. 2014;370(20):1899–1908.
   PubMed Web of Science ®Google Scholar
• Morillo CA, Waskin H, Sosa-Estani S, et al. Benznidazole and posaconazole in eliminating parasites in asymptomatic T. Cruzi Carriers: the STOP-CHAGAS trial. J Am Coll Cardiol. 2017;69(8):939–947.
   PubMed Web of Science ®Google Scholar
• Álvarez MG, Hernández Y, Bertocchi G, et al. New scheme of intermittent benznidazole administration in patients chronically infected with trypanosoma cruzi: a pilot short-term follow-up study with adult patients. Antimicrob Agents Chemother. 2016;60(2):833–837.
   PubMed Web of Science ®Google Scholar
• Blanco SB, Segura EL, Cura EN, et al. Congenital transmission of Trypanosoma cruzi: an operational outline for detecting and treating infected infants in north-western Argentina. Trop Med Int Health. 2000;5(4):293–301.
   PubMed Web of Science ®Google Scholar
• Schijman AG, Altcheh J, Burgos JM, et al. Aetiological treatment of congenital Chagas’ disease diagnosed and monitored by the polymerase chain reaction. J Antimicrob Chemother. 2003;52(3):441–449.
   PubMed Web of Science ®Google Scholar
• Altcheh J, Corral R, Biancardi MA, et al. Anti-F2/3 antibodies as cure marker in children with congenital Trypanosoma cruzi infection. Medicina. 2003;63(1):37–40.
   PubMed Web of Science ®Google Scholar
• Chippaux JP, Salas-Clavijo AN, Postigo JR, et al. Evaluation of compliance to congenital Chagas disease treatment: results of a randomised trial in Bolivia. Trans R Soc Trop Med Hyg. 2013;107(1):1–7.
   PubMed Web of Science ®Google Scholar
• Alonso-Vega C, Billot C, Torrico F. Achievements and challenges upon the implementation of a program for national control of congenital Chagas in Bolivia: results 2004–2009. PLoS Negl Trop Dis. 2013;7(7):e2304.
   PubMed Web of Science ®Google Scholar
• Sosa-Estani S, Viotti R, Segura EL. Therapy, diagnosis and prognosis of chronic Chagas disease: insight gained in Argentina. Memórias do Instituto Oswaldo Cruz. 2009;104:167–180.
   PubMed Web of Science ®Google Scholar
• Sguassero Y, Cuesta CB, Roberts KN, et al. Course of chronic trypanosoma cruzi infection after treatment based on parasitological and serological tests: a systematic review of follow-up studies. PLoS One. 2015;10(10):e0139363.
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano C, Armenti H, et al. Treatment of chronic Chagas’ disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J. 1994;127(1):151–162.
   PubMed Web of Science ®Google Scholar
• Fabbro DL, Danesi E, Olivera V, et al. Trypanocide treatment of women infected with trypanosoma cruzi and its effect on preventing congenital Chagas. PLoS Negl Trop Dis. 2014;8(11):e3312.
   PubMed Web of Science ®Google Scholar
• Fragata-Filho AA, França FF, Fragata C, et al. Evaluation of parasiticide treatment with benznidazol in the electrocardiographic, clinical, and serological evolution of Chagas disease. PLoS Negl Trop Dis. 2016;10(3):e0004508.
   PubMed Web of Science ®Google Scholar
• Fragata Filho AA, Silva M, Boainain E. Ethiological treatment of acute and chronic Chagas’ heart disease. Sao Paulo Med J. 1995;113:867–872.
   PubMedGoogle Scholar
• Gallerano RR, Sosa RR. Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy. Rev Fac Cien Med Univ Nac Cordoba. 2000;57(2):135–162.
   PubMedGoogle Scholar
• Lauria-Pires L, Braga MS, Vexenat AC, et al. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg. 2000;63(3–4):111–118.
   PubMed Web of Science ®Google Scholar
• Storino R, Auger S, Wojdyla D, et al. Análisis descriptivo multivariado de la enfermedad de Chagas en 2,260 pacientes. Rev Argent Cardiol. 1998;66:17–39.
   Google Scholar
• Sosa-Estani S, Cura E, Velazquez E, et al. Etiological treatment of young women infected with Trypanosoma cruzi, and prevention of congenital transmission. Rev Soc Bras Med Trop. 2009;42(5):484–487.
   PubMed Web of Science ®Google Scholar
• Moscatelli G, Moroni S, García-Bournissen F, et al. Prevention of congenital Chagas through treatment of girls and women of childbearing age. Mem Inst Oswaldo Cruz. 2015;110(4):507–509.
   PubMed Web of Science ®Google Scholar
• Murcia L, Simón M, Carrilero B, et al. Treatment of infected women of childbearing age prevents congenital trypanosoma cruzi infection by eliminating the parasitemia detected by PCR. J Infect Dis. 2017;215(9):1452–1458.
   PubMed Web of Science ®Google Scholar
• Alvarez MG, Vigliano C, Lococo B, et al. Prevention of congenital Chagas disease by Benznidazole treatment in reproductive-age women. An observational study. Acta Trop. 2017;174:149–152.
   PubMed Web of Science ®Google Scholar
• Pecoul B, Batista C, Stobbaerts E, et al. The BENEFIT trial: where do we go from here? PLoS Negl Trop Dis. 2016;10(2):e0004343.
   PubMed Web of Science ®Google Scholar
• Yun O, Lima MA, Ellman T, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of médecins Sans Frontières. PLoS Negl Trop Dis. 2009;3(7):e488.
   PubMed Web of Science ®Google Scholar
• Sosa-Estani S, Armenti A, Araujo G, et al. Treatment of Chagas disease with benznidazole and thioctic acid. Medicina. 2004;64(1):1–6.
   PubMed Web of Science ®Google Scholar
• Villar JC, Perez JG, Cortes OL, et al. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev. 2014;(5):CD003463.
   PubMed Web of Science ®Google Scholar
• Sperandio da Silva GM, Mediano MFF, Hasslocher-Moreno AM, et al. Benznidazole treatment safety: the medecins sans frontieres experience in a large cohort of Bolivian patients with Chagas’ disease. J Antimicrob Chemother. 2017;72(9):2596–2601.
   PubMed Web of Science ®Google Scholar
• Colantonio LD, Prado N, Segura EL, et al. electrocardiographic abnormalities and treatment with benznidazole among children with chronic infection by trypanosoma cruzi: a retrospective cohort study. PLoS Negl Trop Dis. 2016;10(5):e0004651.
   PubMed Web of Science ®Google Scholar
• Pinazo MJ, Guerrero L, Posada E, et al. Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease. Antimicrob Agents Chemother. 2013;57(1):390–395.
   PubMed Web of Science ®Google Scholar
• Soy D, Aldasoro E, Guerrero L, et al. Population pharmacokinetics of benznidazole in adult patients with Chagas disease. Antimicrob Agents Chemother. 2015;59(6):3342–3349.
   PubMed Web of Science ®Google Scholar
• Olivera MJ, Cucunubá ZM, Valencia-Hernández CA, et al. Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease. PLoS One. 2017;12(9):e0185033.
   PubMed Web of Science ®Google Scholar
• Salvador F, Sanchez-Montalva A, Martinez-Gallo M, et al. Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with Chagas disease. Clin Infect Dis. 2015;61(11):1688–1694.
   PubMed Web of Science ®Google Scholar
• Carlier Y, Torrico F, Sosa-Estani S, et al. Congenital Chagas disease: recommendations for diagnosis, treatment and control of newborns, siblings and pregnant women. PLoS Negl Trop Dis. 2011;5(10):e1250.
   PubMed Web of Science ®Google Scholar
• Model prescribing information: drugs used in parasitic diseases. Geneva: World Health Organization; 1995.
   Google Scholar
• Moretti E, Basso B, Castro I, et al. Chagas’ disease: study of congenital transmission in cases of acute maternal infection. Rev Soc Bras Med Trop. 2005;38(1):53–55.
   PubMed Web of Science ®Google Scholar
• Correa VR, Barbosa FG, Melo Junior CA, et al. Uneventful benznidazole treatment of acute Chagas disease during pregnancy: a case report. Rev Soc Bras Med Trop. 2014;47(3):397–400.
   PubMed Web of Science ®Google Scholar
• Garcia-Bournissen F, Moroni S, Marson ME, et al. Limited infant exposure to benznidazole through breast milk during maternal treatment for Chagas disease. Arch Dis Child. 2015;100(1):90–94.
   PubMed Web of Science ®Google Scholar
• Manne JM, Snively CS, Ramsey JM, et al. Barriers to treatment access for Chagas disease in Mexico. PLoS Negl Trop Dis. 2013;7(10):e2488.
   PubMed Web of Science ®Google Scholar
• Sanchez DR, Traina MI, Hernandez S, et al. Chagas disease awareness among Latin American immigrants living in Los Angeles, California. Am J Trop Med Hyg. 2014;91(5):915–919.
   PubMed Web of Science ®Google Scholar
• Mesu VKBK, Kalonji WM, Bardonneau C, et al. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet. 2018;391(10116):144–154.
   PubMed Web of Science ®Google Scholar
• Bahia MT, De Andrade IM, Martins TA, et al. Fexinidazole: a potential new drug candidate for Chagas disease. PLoS Negl Trop Dis. 2012;6(11):e1870.
   PubMed Web of Science ®Google Scholar
• Caldas S, Caldas IS, Cecilio AB, et al. Therapeutic responses to different anti-Trypanosoma cruzi drugs in experimental infection by benznidazole-resistant parasite stock. Parasitology. 2014;141(12):1628–1637. doi:10.1017/S0031182014000882.
   PubMed Web of Science ®Google Scholar
• Bahia MT, Nascimento AF, Mazzeti AL, et al. Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease. Antimicrob Agents Chemother. 2014;58(8):4362–4370.
   PubMed Web of Science ®Google Scholar
• Pinazo M-J, Thomas MC, Bua J, et al. Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review. Expert Rev Anti Infect Ther. 2014;12(4):479–496.
   PubMed Web of Science ®Google Scholar
• Pinazo M-J, Pinto J, Ortiz L, et al. A strategy for scaling up access to comprehensive care in adults with Chagas disease in endemic countries: the Bolivian Chagas platform. PLoS Negl Trop Dis. 2017;11(8):e0005770.
   PubMed Web of Science ®Google Scholar
• Sartor P, Colaianni I, Cardinal MV, et al. Improving access to Chagas disease diagnosis and etiologic treatment in remote rural communities of the Argentine Chaco through strengthened primary health care and broad social participation. PLoS Negl Trop Dis. 2017;11(2):e0005336.
   PubMed Web of Science ®Google Scholar
• Marchiol A, Forsyth CJ, Bernal O, et al. Increasing access to comprehensive care for Chagas disease: development of a patient-centered model in Colombia. Rev Panam Salud Publica. 2017;41:e153.
   PubMed Web of Science ®Google Scholar